Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.

Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM.

BMJ Open. 2017 Dec 5;7(12):e017917. doi: 10.1136/bmjopen-2017-017917.

2.

Publication of interventional phase 3 and 4 clinical trials in radiation oncology: an observational study.

Pérez-Alija J, Gallego P, Linares I, Ambroa E, Pedro A.

BMJ Open. 2017 Sep 21;7(9):e016040. doi: 10.1136/bmjopen-2017-016040.

3.

Underreporting of Research Biopsies from Clinical Trials in Oncology.

Parseghian CM, Raghav K, Wolff RA, Ensor J Jr, Yao J, Ellis LM, Tam AL, Overman MJ.

Clin Cancer Res. 2017 Nov 1;23(21):6450-6457. doi: 10.1158/1078-0432.CCR-17-1449. Epub 2017 Jul 28.

PMID:
28754815
4.

Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013.

Khan A, Fahl Mar K, Faucett J, Khan Schilling S, Brown WA.

World Psychiatry. 2017 Jun;16(2):181-192. doi: 10.1002/wps.20421. Erratum in: World Psychiatry. 2017 Oct;16(3):328.

5.

Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding.

Al-Badriyeh D, Alameri M, Al-Okka R.

BMJ Open. 2017 Jan 27;7(1):e012648. doi: 10.1136/bmjopen-2016-012648. Review.

6.

Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history.

Mooney LA, Fay L.

BMJ Open. 2016 Jul 18;6(7):e012362. doi: 10.1136/bmjopen-2016-012362.

7.

Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study.

Foster PD, Camacho X, Vigod S, Yao Z, Juurlink DN, Paterson JM, Mamdani MM, Martins D, Gomes T.

CMAJ Open. 2016 Jun 10;4(2):E292-7. doi: 10.9778/cmajo.20150095. eCollection 2016 Apr-Jun.

8.
9.

ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.

Schwartz LM, Woloshin S, Zheng E, Tse T, Zarin DA.

Ann Intern Med. 2016 Sep 20;165(6):421-30. doi: 10.7326/M15-2658. Epub 2016 Jun 14.

10.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.

11.
12.

Clinical trial transparency.

Sasich LD.

CMAJ. 2015 Oct 6;187(14):1077. doi: 10.1503/cmaj.1150063. No abstract available.

13.

Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study.

van den Bogert CA, Souverein PC, Brekelmans CT, Janssen SW, van Hunnik M, Koëter GH, Leufkens HG, Bouter LM.

BMJ Open. 2015 Jul 7;5(7):e007827. doi: 10.1136/bmjopen-2015-007827.

14.

Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.

Williams RJ, Tse T, DiPiazza K, Zarin DA.

PLoS One. 2015 May 26;10(5):e0127242. doi: 10.1371/journal.pone.0127242. eCollection 2015.

15.

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA.

J Pers Med. 2014 Mar 7;4(1):52-64. doi: 10.3390/jpm4010052.

16.

Discontinuation and non-publication of surgical randomised controlled trials: observational study.

Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A.

BMJ. 2014 Dec 9;349:g6870. doi: 10.1136/bmj.g6870.

17.

Clinicaltrials.gov: Is the Glass Half Full?

Guharoy V.

Hosp Pharm. 2014 Nov;49(10):893-5. doi: 10.1310/hpj4910-893. No abstract available.

18.
19.

Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study.

Smithy JW, Downing NS, Ross JS.

JAMA Intern Med. 2014 Sep;174(9):1518-20. doi: 10.1001/jamainternmed.2014.3438. No abstract available.

20.

Protections for clinical trials in low and middle income countries need strengthening not weakening.

Dal-Ré R, Ndebele P, Higgs E, Sewankambo N, Wendler D.

BMJ. 2014 Jul 4;349:g4254. doi: 10.1136/bmj.g4254. No abstract available. Erratum in: BMJ. 2014;349:g4516.

Supplemental Content

Support Center